Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector

US8101739B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Nancy Sullivan · Kensington, US
• Bimal Chakrabarti · Gaithersburg, US
• Zhi-yong Yang · Potomac, US
• Maria Grazia Pau · Leiden, NL
• Jaap Goudsmit · Amsterdam, NL
• Gary J. Nabel · Cambridge, US

Key dates

• Filing date: Sep 27, 2005
• Grant date: Jan 24, 2012
• Expiry date: Jun 7, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2840/44
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same.